The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II (INSPIRE) trial of pembrolizumab (pembro) with serial immune and genomic profiling in patients (pts) with metastatic triple negative breast cancer (mTNBC).
 
Zachary William Neil Veitch
No Relationships to Disclose
 
David W. Cescon
Consulting or Advisory Role - Genomic Health
Research Funding - GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Sawako Elston
No Relationships to Disclose
 
Scott Lien
No Relationships to Disclose
 
Cindy Yang
No Relationships to Disclose
 
Ben X Wang
No Relationships to Disclose
 
Hal K. Berman
No Relationships to Disclose
 
Marcus O. Butler
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; EMD Serono; GlaxoSmithKline; Immunocore; Immunovaccine; Merck; Novartis
Research Funding - Merck
Expert Testimony - Merck
 
Eitan Amir
Honoraria - Apobiologix
 
Christine Elser
No Relationships to Disclose
 
Sevan Hakgor
No Relationships to Disclose
 
Amanda Giesler
No Relationships to Disclose
 
Trevor John Pugh
No Relationships to Disclose
 
Pamela S Ohashi
Consulting or Advisory Role - Symphony Evolution (Inst)
 
Lillian L. Siu
Leadership - Agios (I)
Consulting or Advisory Role - AstraZeneca/MedImmune; Merck; MorphoSys; Symphony Evolution
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Symphony Evolution (Inst)
 
Philippe L. Bedard
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cascadian Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); PTC Therapeutics (Inst); Sanofi (Inst); SERVIER (Inst); SignalChem (Inst)